LE
Lexaria Bioscience Corp.
LEXX · NASDAQ
$3.43 +4.10% (+$0.13)
1M -69.26%
Market Cap $5.27M
P/E Ratio -
Div. Yield -
ROE 160.72%
Bulios Fair Price
$1.77
48.3% downside
Current Price
$3.43
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LEXX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
50 /100
Fair P/B 1.11x
P/S 27.17x
P/FFO N/A
Growth
78 /100
Growing Book val. growth 27.82%
Rev. growth 40.34%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 3,973.16%
Gross margin 100.00%
FCF margin 3,880.08%
Quality
0 /100
Poor ROA 161.71%
ROIC 174.06%
Asset turnover 0.04x
Debt
100 /100
Low Current ratio 10.60x
Debt/Equity 0.02x
Debt/Assets N/A
Stability
22 /100
Unstable EPS volatility 47.46%
Beta 0.34x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LEXX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Richard C. Christopher
Employees
7
Headquarters
Kelowna
Upcoming events
28 OCT
Earnings
Upcoming earnings report